Cipher Pharmaceuticals Inc.
https://www.cipherpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cipher Pharmaceuticals Inc.
Healthtech Leaders Discuss Impact (And Risks) Of Generative AI and AI In Health Care
AI and generative AI ruled much of the discussion at HLTH Europe 2024. A panel of health care leaders from Microsoft, Philips, insitro and Johnson & Johnson discussed how these new technologies are already transforming health care and pointed to risks and challenges.
Big Pharma Leads Development Of Novel Antibody-Drug Conjugates
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
Dyne Hopes DM1 And DMD Mid-Stage Data Can Lead To Accelerated Approval
Phase I/II data for its ADC candidates in myotonic dystrophy type 1 and Duchenne muscular dystrophy indicate potential for biomarker-based accelerated approval in both diseases, Dyne asserts.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Innocutis Medical LLC (Innocutis Holding LLC
- JSJ Pharmaceuticals)
- Cipher Pharmaceuticals US LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice